Scientists from the Medical University of Warsaw found that more than half of patients with myelodysplasia (one of the types of malignant hematopoiesis) die within five years of diagnosis. Research published British Journal of Health.
The study used data from the European Registry on patients with low-risk myelodysplasia. Data were collected from 2008 to 2019. Of the 2396 patients studied, 900 died within the first 4.7 years after diagnosis. Acute myeloid leukemia, infections, and cardiovascular disease were most common in 20.1%, 17.8%, and 9.8% of patients, respectively.
Five-year overall survival was 47.3%, respectively. At the same time, the relative survival rate in the first year is very high, 94.3%.
Myelodysplastic syndromes are a group of diseases characterized by a violation of the myeloid branch of hematopoiesis. The disease is based on damage to bone marrow stem cells. This leads to a disruption in the production of immune cells: neutrophils, eosinophils, basophils and monocytes, as well as red blood cells and platelets.